Related Experiment Video
Updated: Jan 8, 2026

10:16
Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis
Published on: December 16, 2016
50.7K
Microplastics as environmental modifiers of lung disease
Emmanouela Epeslidou1, Julia S Scott1, Bim de Klein1
1University Medical Center Utrecht, Utrecht, The Netherlands.
EMBO Molecular Medicine
|December 11, 2025
Summary
Microplastics are airborne contaminants linked to respiratory diseases like lung cancer and asthma. Understanding how particle properties affect lung cells is crucial for addressing this growing health concern.
Area of Science:
- Environmental Science
- Toxicology
- Pulmonology
Background:
- Human environmental changes are altering disease patterns, with airborne microplastics emerging as a significant lung health concern.
- Inhalation of microplastics, especially from indoor synthetic fibers, raises alarms for respiratory health.
- Existing studies link microplastic exposure to lung cancer, asthma, COPD, and fibrosis, but mechanisms are unclear.
Purpose of the Study:
- To review evidence on how microplastic properties influence biological outcomes in the lungs.
- To outline the effects of different polymer types, sizes, and aging states on lung cells.
- To identify knowledge gaps and suggest future research directions.
Main Methods:
- Literature review integrating epidemiological and experimental studies.
- Analysis of how particle characteristics (type, size, aging) impact cellular mechanisms.
- Examination of biological outcomes including inflammation, oxidative stress, and epigenetic changes.
Main Results:
- Microplastic properties significantly influence biological responses in lung cells.
- Mechanisms include inflammation, oxidative stress, ferroptosis, epithelial-mesenchymal transition, and epigenetic alterations.
- Microplastics may act as environmental modifiers exacerbating respiratory disease progression.
Conclusions:
- Microplastics pose a complex and persistent threat to lung health.
- Further research with standardized metrics and realistic doses is needed.
- Coordinated scientific and regulatory action is essential to mitigate risks.
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K

